Aytu BioPharma, Inc.

Symbol: AYTU

NASDAQ

3.21

USD

Market price today

  • -1.0645

    P/E Ratio

  • -0.0176

    PEG Ratio

  • 17.87M

    MRK Cap

  • 0.00%

    DIV Yield

Aytu BioPharma, Inc. (AYTU) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.63%

Operating Profit Margin

-0.08%

Net Profit Margin

-0.17%

Return on Assets

-0.13%

Return on Equity

-0.46%

Return on Capital Employed

-0.12%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Joshua R. Disbrow
Full-time employees:150
City:Englewood
Address:373 Inverness Parkway
IPO:2008-09-25
CIK:0001385818

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

General Outlook

When we look at how much money they make before expenses, they keep 0.632% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.084%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.169%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.127% return, is a testament to Aytu BioPharma, Inc.'s adeptness in optimizing resource deployment. Aytu BioPharma, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.458%. Furthermore, the proficiency of Aytu BioPharma, Inc. in capital utilization is underscored by a remarkable -0.123% return on capital employed.

Stock Prices

Aytu BioPharma, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $2.95, while its low point bottomed out at $2.85. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Aytu BioPharma, Inc.'s stock market.

Liquidity Ratios

Analyzing AYTU liquidity ratios reveals its financial health of the firm. The current ratio of 111.19% gauges short-term asset coverage for liabilities. The quick ratio (76.23%) assesses immediate liquidity, while the cash ratio (30.43%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio111.19%
Quick Ratio76.23%
Cash Ratio30.43%

Profitability Ratios

AYTU profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -17.43% underscores its earnings before tax deductions. The effective tax rate stands at -7.30%, revealing its tax efficiency. The net income per EBT, 96.91%, and the EBT per EBIT, 207.78%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -8.39%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-17.43%
Effective Tax Rate-7.30%
Net Income per EBT96.91%
EBT per EBIT207.78%
EBIT per Revenue-8.39%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.11, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding76
Days of Inventory Outstanding131
Operating Cycle240.03
Days of Payables Outstanding106
Cash Conversion Cycle134
Receivables Turnover3.35
Payables Turnover3.46
Inventory Turnover2.78
Fixed Asset Turnover30.21
Asset Turnover0.75

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 1.11, and free cash flow per share, 1.11, depict cash generation on a per-share basis. The cash per share value, 3.54, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.06, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share1.11
Free Cash Flow per Share1.11
Cash per Share3.54
Operating Cash Flow Sales Ratio0.06
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio0.38
Short Term Coverage Ratio5.74

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 12.22%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.49, we discern the balance between debt and equity financing. The long-term debt to capitalization, 31.31%, and total debt to capitalization, 32.81%, ratios shed light on its capital structure. An interest coverage of 2.14 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio12.22%
Debt Equity Ratio0.49
Long Term Debt to Capitalization31.31%
Total Debt to Capitalization32.81%
Interest Coverage2.14
Cash Flow to Debt Ratio0.38
Company Equity Multiplier4.00

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 32.16, provides a glimpse into top-line earnings distributed across each share. Net income per share, -5.11, reflects the portion of profit attributed to each share. The book value per share, 11.78, represents the net asset value distributed per share, while the tangible book value per share, -5.87, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share32.16
Net Income Per Share-5.11
Book Value Per Share11.78
Tangible Book Value Per Share-5.87
Shareholders Equity Per Share11.78
Interest Debt Per Share4.90

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 11.10%, indicates top-line expansion, while the gross profit growth, 27.44%, reveals profitability trends. EBIT growth, -145.86%, and operating income growth, -145.86%, offer insights into operational profitability progression. The net income growth, 84.52%, showcases bottom-line expansion, and the EPS growth, 99.66%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth11.10%
Gross Profit Growth27.44%
EBIT Growth-145.86%
Operating Income Growth-145.86%
Net Income Growth84.52%
EPS Growth99.66%
EPS Diluted Growth99.66%
Weighted Average Shares Growth4444.52%
Weighted Average Shares Diluted Growth4444.52%
Operating Cash Flow Growth82.21%
Free Cash Flow Growth82.21%
10-Year Revenue Growth per Share-85.30%
5-Year Revenue Growth per Share-97.08%
3-Year Revenue Growth per Share-73.70%
10-Year Operating CF Growth per Share99.97%
5-Year Operating CF Growth per Share99.97%
3-Year Operating CF Growth per Share98.78%
10-Year Net Income Growth per Share99.93%
5-Year Net Income Growth per Share99.83%
3-Year Net Income Growth per Share68.82%
10-Year Shareholders Equity Growth per Share100.09%
5-Year Shareholders Equity Growth per Share-99.71%
3-Year Shareholders Equity Growth per Share-97.20%
Receivables Growth33.28%
Inventory Growth10.56%
Asset Growth-0.84%
Book Value per Share Growth-98.12%
Debt Growth-10.05%
R&D Expense Growth-71.64%
SGA Expenses Growth0.28%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, -1,280,150.4, captures the company's total value, considering both debt and equity. Income quality, 0.30, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.27, gauges operational efficiency, while the research and development to revenue, 3.81%, highlights investment in innovation.

cards.indicatorcards.value
Enterprise Value-1,280,150.4
Income Quality0.30
Sales General and Administrative to Revenue0.27
Research and Development to Revenue3.81%
Intangibles to Total Assets43.21%
Stock-Based Compensation to Revenue5.63%
Graham Number36.79
Return on Tangible Assets-22.00%
Graham Net Net-13.90
Working Capital3,817,000
Tangible Asset Value-19,613,000
Net Current Asset Value-24,274,000
Average Receivables25,324,500
Average Payables12,232,500
Average Inventory11,422,000
Days Sales Outstanding98
Days Payables Outstanding121
Days of Inventory On Hand107
ROIC-30.53%
ROE-0.43%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.54, and the price to book ratio, 0.54, reflect the market's valuation relative to the company's book value. The price to sales ratio, 0.18, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 2.92, and price to operating cash flows, 2.90, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio0.54
Price to Book Ratio0.54
Price to Sales Ratio0.18
Price Cash Flow Ratio2.90
Price Earnings to Growth Ratio-0.02
Enterprise Value Multiple-68.46
Price Fair Value0.54
Price to Operating Cash Flow Ratio2.90
Price to Free Cash Flows Ratio2.92
Price to Tangible Book Ratio0.14
Enterprise Value to Sales-0.01
Enterprise Value Over EBITDA0.17
EV to Operating Cash Flow0.25
Earnings Yield-319.08%
Free Cash Flow Yield-95.98%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Aytu BioPharma, Inc. (AYTU) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -1.064 in 2024.

What is the ticker symbol of Aytu BioPharma, Inc. stock?

The ticker symbol of Aytu BioPharma, Inc. stock is AYTU.

What is company IPO date?

IPO date of Aytu BioPharma, Inc. is 2008-09-25.

What is company current share price?

Current share price is 3.210 USD.

What is stock market cap today?

The market cap of stock today is 17871996.000.

What is PEG ratio in 2024?

The current -0.018 is -0.018 in 2024.

What is the number of employees in 2024?

In 2024 the company has 150.